Canada markets close in 2 hours 3 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.38+0.21 (+0.99%)
As of 01:57PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close21.17
Open21.17
Bid21.30 x 400
Ask21.49 x 100
Day's Range20.89 - 21.65
52 Week Range7.41 - 24.17
Volume204,006
Avg. Volume1,478,855
Market Cap1.628B
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
  • GlobeNewswire

    Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

    – Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a monotherapy continues in parallel – SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced dosing of the first patient with KO-2806, the Company’s next-generation farnesyl transferase

  • GlobeNewswire

    Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 1, 2024, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 93,000 shares of common stock to two (2) new employees under

  • Insider Monkey

    Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript

    Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript February 27, 2024 Kura Oncology, Inc. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.56. Kura Oncology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]